Prognostic utility of a semiquantitative spinal deformity index

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization. WHO Technical Report Series 843. Geneva: World Health Organization; 1994. Kanis, 1994, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group, Osteoporos Int., 4, 368, 10.1007/BF01622200 Riggs, 1995, The worldwide problem of osteoporosis: insights afforded by epidemiology, Bone, 17, 505S, 10.1016/8756-3282(95)00258-4 Melton, 1993, Prevalence and incidence of vertebral deformities, Osteoporos Int., 3, 113, 10.1007/BF01623271 Bjarnason, 2001, Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis, Osteoporos Int., 12, 922, 10.1007/s001980170020 Delmas, 2003, Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial, Bone, 33, 522, 10.1016/S8756-3282(03)00241-2 Watts, 2003, Risedronate prevents new vertebral fractures in postmenopausal women at high risk, J. Clin. Endocrinol. Metab., 88, 542, 10.1210/jc.2002-020400 Genant, 1993, Vertebral fracture assessment using a semiquantitative technique, J. Bone Miner. Res., 8, 1137, 10.1002/jbmr.5650080915 Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, JAMA, 282, 637, 10.1001/jama.282.7.637 Hosmer, 1989, 135 Roux, 2004, Efficacy of risedronate on clinical vertebral fractures within six months, Curr. Med. Res. Opin., 20, 433, 10.1185/030079903125003125